Sermorelin vs. Ipamorelin vs. Tesamorelin
A Research Comparison
Disclaimer: For research use only, not for human use. All comparisons are based on published research data.
Ipamorelin 10mg
In stock
Introduction
Sermorelin, Ipamorelin, and Tesamorelin are three distinct peptides studied for their ability to influence the growth hormone (GH) axis — but they act at different points in the pathway and have different structural characteristics.123 This comparison outlines their molecular differences, mechanisms, and research uses.
At a Glance: Key Differences
Insert Figure 1: Side-by-side comparison table of Sermorelin, Ipamorelin, and Tesamorelin.ALT: “Table comparing Sermorelin, Ipamorelin, and Tesamorelin on structure, mechanism, and research uses.”Caption: “Figure 1. Summary of differences between Sermorelin, Ipamorelin, and Tesamorelin in research contexts.”
Feature
Sermorelin
Ipamorelin
Tesamorelin
Type
Synthetic GHRH analog (1–29 aa)
Growth hormone secretagogue (GHS) pentapeptide
Modified GHRH analog
Primary Target
GHRH receptor (pituitary)
Ghrelin receptor (GHS-R1a)
Main Effect
Pulsatile GH release via GHRH axis
GH release without cortisol or prolactin spikes
GH release, reduced visceral adipose tissue
Half-Life
~10–20 min
~2 hours
~30 min
Notable Study Area
Diagnostic GH testing, aging models
Muscle and tendon recovery, anti-catabolic research
HIV-associated lipodystrophy, metabolic research
Mechanism of Action Differences
Sermorelin
Mimics endogenous GHRH to trigger physiologic GH pulses.1
Preserves negative feedback loops via somatostatin.
Ipamorelin
Selectively activates ghrelin receptors, stimulating GH release without significant effect on other pituitary hormones.2
Often studied alongside CJC-1295 for combined effects.
Tesamorelin
Modified GHRH analog designed for enhanced stability.3
In research, reduces visceral adipose tissue while increasing GH and IGF-1.
Research Use Focus Areas
ALT: “Venn diagram comparing research applications of Sermorelin, Ipamorelin, and Tesamorelin.”
Sermorelin: GH axis testing, aging-related hormone studies.1
Ipamorelin: Recovery and repair models, muscle preservation.2
Tesamorelin: Fat metabolism and distribution studies, particularly in visceral adiposity models.3
Summary
While all three peptides interact with the GH axis, Sermorelin acts through GHRH receptors to produce natural GH pulses, Ipamorelin works via ghrelin receptors with high selectivity, and Tesamorelin is a stabilized GHRH analog often studied for metabolic effects. Choice of peptide in research depends on the target pathway and study goals.
FAQs
What is the difference between Sermorelin and Ipamorelin?
Sermorelin is a synthetic GHRH analog that stimulates physiologic GH pulses via the pituitary, while Ipamorelin is a selective ghrelin receptor agonist that triggers GH release without affecting other pituitary hormones.
How does Tesamorelin differ from Sermorelin?
Tesamorelin is a stabilized GHRH analog with a longer half-life, often studied for its effects on visceral fat reduction, whereas Sermorelin is primarily used for GH axis stimulation and testing.
Can these peptides be used together in research?
Some research protocols combine GH axis–modulating peptides, but study design depends on specific goals and pathway targets.
Related Pages
What is Ipamorelin
What is Sermorelin
What is BPC-157
What is TB-500
References
Thorner MO, et al. Sermorelin: a growth hormone–releasing hormone analog. J Clin Endocrinol Metab. 1986;62(4):648–653. https://pubmed.ncbi.nlm.nih.gov/3004674/
Svensson J, et al. Ipamorelin, a new growth hormone releasing peptide in humans. J Clin Endocrinol Metab. 2000;85(1): 282–288. https://pubmed.ncbi.nlm.nih.gov/10634381/
Falutz J, et al. Effects of tesamorelin, a growth hormone–releasing factor analog, in HIV patients with abdominal fat accumulation. N Engl J Med. 2007;357(23):2359–2370. https://pubmed.ncbi.nlm.nih.gov/18057337/